Matches in Wikidata for { <http://www.wikidata.org/entity/Q65368744> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q65368744 description "clinical trial" @default.
- Q65368744 description "ensayu clínicu" @default.
- Q65368744 description "klinisch onderzoek" @default.
- Q65368744 description "клінічне випробування" @default.
- Q65368744 name "A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)" @default.
- Q65368744 name "A Post-marketing Study Evaluating Eslicarbazepine Acetate" @default.
- Q65368744 type Item @default.
- Q65368744 label "A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)" @default.
- Q65368744 label "A Post-marketing Study Evaluating Eslicarbazepine Acetate" @default.
- Q65368744 prefLabel "A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)" @default.
- Q65368744 prefLabel "A Post-marketing Study Evaluating Eslicarbazepine Acetate" @default.
- Q65368744 P1132 Q65368744-0A02AF4E-F244-42B0-9872-E9C0D2E705D7 @default.
- Q65368744 P1476 Q65368744-69387C35-C70F-43E2-9CB0-74EAA50413D7 @default.
- Q65368744 P17 Q65368744-0BDC7CC4-D177-49BC-B597-3488EF4634D6 @default.
- Q65368744 P17 Q65368744-2074803C-2DE6-45EA-941E-3B1DA548AF7D @default.
- Q65368744 P17 Q65368744-4D468DB1-AEDA-4BA9-957E-B34BCFF12D43 @default.
- Q65368744 P17 Q65368744-8FA7FD63-FE94-4691-9BB5-CF922528C5BB @default.
- Q65368744 P17 Q65368744-96A6EB12-3B6F-4CE0-AE95-F914853D6741 @default.
- Q65368744 P17 Q65368744-9CB31C5A-64F4-4F88-B822-9C9E51AA7C9D @default.
- Q65368744 P17 Q65368744-BFB785C0-70BC-4785-92DD-215836159A18 @default.
- Q65368744 P17 Q65368744-F4A58FC3-FD83-4A92-83BD-67C833153F5D @default.
- Q65368744 P2899 Q65368744-198A113B-7F2F-4CF9-99A7-9E2715DE520D @default.
- Q65368744 P3098 Q65368744-8C412DA8-F5D0-4F69-A7B2-818BA73DC1A5 @default.
- Q65368744 P31 Q65368744-4B1CB7A0-DA67-4AD7-B833-8C9D0469FE49 @default.
- Q65368744 P580 Q65368744-F2F385AD-7CE4-4239-B539-7292A230FFAA @default.
- Q65368744 P582 Q65368744-4671E01C-60B5-4421-9864-EA6027860465 @default.
- Q65368744 P8363 Q65368744-BE9B8B09-508E-4EAD-8A29-DCFA105690C7 @default.
- Q65368744 P1132 "+254" @default.
- Q65368744 P1476 "An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Prospective Study Evaluating Retention Rate, Seizure Control and Tolerability of Eslicarbazepine Acetate (ESL) as Adjunctive Treatment to One Baseline Antiepileptic Drug in Adult Patients With Partial-Onset Seizures With or Without Secondary Generalisation" @default.
- Q65368744 P17 Q142 @default.
- Q65368744 P17 Q145 @default.
- Q65368744 P17 Q183 @default.
- Q65368744 P17 Q20 @default.
- Q65368744 P17 Q213 @default.
- Q65368744 P17 Q27 @default.
- Q65368744 P17 Q34 @default.
- Q65368744 P17 Q35 @default.
- Q65368744 P2899 "+18" @default.
- Q65368744 P3098 "NCT01830400" @default.
- Q65368744 P31 Q30612 @default.
- Q65368744 P580 "2012-04-01T00:00:00Z" @default.
- Q65368744 P582 "2014-03-01T00:00:00Z" @default.
- Q65368744 P8363 Q818574 @default.